Reactivity of ALK1-Positive Lymphomas With Antibodies Detecting T-Cell–Associated Antigens
| Histopathologic Subtypes . | Antigens . | Conclusion* . | ||||
|---|---|---|---|---|---|---|
| CD3 (+/tested) . | CD43 (+/tested) . | CD45RO (+/tested) . | CBF.783-151 (+/tested) . | T Phenotype3-152 (+/tested) . | Null Phenotype3-153 (+/tested) . | |
| Common type | 12/44 | 23/55 | 21/39 | 14/26 | 36/78 (46%) | 19/78 (24%) |
| Lymphohistiocytic | 2/5 | 7/9 | 5/9 | 3/4 | 10/14 (71%) | 1/14 (7%) |
| Small cell variant | 3/7 | 5/5 | 3/4 | 7/7 | 7/7 (100%) | 0/7 |
| Giant cell | 0 | 1/1 | 0 | 1/1 | 1/2 | 0/2 |
| Mixed | 5/12 | 6/9 | 6/10 | 7/9 | 12/17 (70%) | 3/17 (17%) |
| Unclassifiable | 1/2 | — | 0 | 0 | 1/5 | 1/5 |
| Total | 23/70 (32%) | 42/79 (53%) | 35/65 (54%) | 31/47 (66%) | 68/123 (54%) | 24/123 (20%) |
| Histopathologic Subtypes . | Antigens . | Conclusion* . | ||||
|---|---|---|---|---|---|---|
| CD3 (+/tested) . | CD43 (+/tested) . | CD45RO (+/tested) . | CBF.783-151 (+/tested) . | T Phenotype3-152 (+/tested) . | Null Phenotype3-153 (+/tested) . | |
| Common type | 12/44 | 23/55 | 21/39 | 14/26 | 36/78 (46%) | 19/78 (24%) |
| Lymphohistiocytic | 2/5 | 7/9 | 5/9 | 3/4 | 10/14 (71%) | 1/14 (7%) |
| Small cell variant | 3/7 | 5/5 | 3/4 | 7/7 | 7/7 (100%) | 0/7 |
| Giant cell | 0 | 1/1 | 0 | 1/1 | 1/2 | 0/2 |
| Mixed | 5/12 | 6/9 | 6/10 | 7/9 | 12/17 (70%) | 3/17 (17%) |
| Unclassifiable | 1/2 | — | 0 | 0 | 1/5 | 1/5 |
| Total | 23/70 (32%) | 42/79 (53%) | 35/65 (54%) | 31/47 (66%) | 68/123 (54%) | 24/123 (20%) |
*In 31 cases, the phenotype of malignant cells could not be determined because these cases had been investigated with a limited panel of antibodies and no material was available for further immunostaining.
CBF.78 is an antibody from the authors' laboratories that detects a T-cell–associated antigen closely related to CD43 antigen.
Tumors were considered to be of T phenotype when CD3 and/or CD43 and/or CBF78 and/or CD45RO were positive in conjunction with negative staining for CD20 and/or CD79a and/or CD45RA and CD76 and/or MB2.
Tumors were considered to be of null phenotype when negative for CD3 and/or CD43 and/or/CBF78 in conjunction with negative staining for CD20 and/or CD79a and/or CD45RA and CD76 and/or MB2. In addition, 20 cases investigated in frozen sections were negative with a large panel of monoclonal antibodies directed against T, B, and macrophage-associated antigens.